Entity

Time filter

Source Type


Sun Q.-P.,Sun Yat Sen University | Li L.-Y.,Sun Yat Sen University | Chen Z.,University of Utah | Chen Z.,GP Medical Technologies Ltd. | And 7 more authors.
Journal of Molecular Diagnostics | Year: 2010

Fusion of the prostate-specific and androgen-regulated transmembrane-serine protease gene (TMPRSS2) with the erythroblast transformation-specific (ETS) family members is the most common genetic alteration in prostate cancer. However, the biological and clinical role of TMPRSS2-ETS fusions in prostate cancer, especially in problematic prostate needle core biopsies, has not been rigorously evaluated. We randomly collected 85 specimens including 50 archival prostate cancer tissue blocks, 15 normal prostate specimens, and 20 benign prostatic hyperplasia specimens for TMPRSS2-ETS fusion analyses. Moreover, the fusion status in an additional 20 patients with initial negative biopsies who progressed to biopsypositive prostate cancer at subsequent follow-ups was also characterized. Fluorescently labeled probes specific for ERG-related rearrangements involving the TMPRSS2-ERG fusion as well as TMPRSS2-ETV1 and TMPRSS2-ETV4 were used to assess samples for gene rearrangements indicative of malignancy under a design of sequential trial. Rearrangements involving TMPRSS2-ETS fusions were detected in 90.0% of the 50 postoperative prostate cancer samples. The positive rate for the rearrangements in the initial prostate cancer-negative biopsies of 20 patients who eventually progressed to prostate cancer was 60.0% (12/20). Our preliminary study demonstrates that the clinical utility of TMPRSS2-ETS fusion detection as a biomarker and ancillary diagnostic tool for the early diagnosis of prostate cancer is promising, given this approach shows significant high sensitivity and specificity in detection. Copyright © American Society for Investigative Pathology and the Association for Molecular Pathology. Source


Wang S.,Capital Medical University | Yang H.,GP Medical Technologies Ltd. | Zhang H.,GP Medical Technologies Ltd. | Yang F.,GP Medical Technologies Ltd. | And 9 more authors.
Cancer Genetics and Cytogenetics | Year: 2010

We report a novel system (W2600) that is based on the technology of surface plasmon resonance (SPR) to genotype human papillomavirus (HPV). The system permitted detection of 24 known HPV genotypes, including 16 high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 81) and 8 low-risk types (HPV 6, 11, 40, 42, 43, 44, 54, 70). Analytical performance of W2600 for HPV genotyping was evaluated by HPV DNA derived from the liquid cervical cytology specimens of 560 patients with atypical squamous cells of undetermined significance or above. In comparison with clonal sequence analysis, 358 of 560 (64%) and 355 of 560 (63%) cases were found to be positive within the 24 HPV genotypes by W2600 and sequence analysis, respectively. Concordance between these two methods was at 555 of 560 (99%) (kappa = 0.98, P < 0.001); only 5 of the 560 (1%) cases had discordant results. No cross-hybridizations were observed with the W2600 system, and the spectrum of HPV genotypes identified by W2600 included all the 16 high-risk genotypes. These data demonstrate that the SPR-based W2600 system is highly sensitive and specific in HPV genotyping and can provide an effective approach for such application in a clinical setting. © 2010 Elsevier Inc. Source


Wang S.,Capital Medical University | Liu N.,GP Medical Technologies Ltd. | Jia C.,Capital Medical University | Li Y.,Capital Medical University | And 3 more authors.
Cancer Genetics and Cytogenetics | Year: 2010

Surface plasmon resonance (SPR)-based technologies have been widely used to study biomolecular interactions including receptor-ligand, DNA-protein, and protein-protein interactions. In this pilot study, we used chromosome 21 as the genetic marker to appreciate the value of using SPR technology for the detection of chromosome aneuploidy. Four normal and four trisomy 21 samples were used in this study. Chromosomes 1- (as the internal control) and 21-specific sequence-tagged sites were used as markers for detection. Resonance unit ratios of chromosome 21 sequence-tagged site (STS) to chromosome 1 STS were calculated to interpret analytic results. The ratios in the normal samples ranged from 0.96 to 2.83, whereas in trisomy 21 samples, the ratios were from 6.96 to 16.30, significantly higher than those of the normal samples. These findings strongly indicate that SPR technology is suitable for the detection of trisomy 21. © 2010 Elsevier Inc. Source

Discover hidden collaborations